NK cell-based immunotherapy for treating cancer: Will it be promising?

Korean Journal of Hematology

Volumn 46, Issue 1, 2011, Pages 3-5

  Cho, Duck ^a,b   Kim, Sang Ki ^c   Carson, William E ^d  

^a Chonnam National University Medical School   (South Korea)

^b Chonnam National University Hwasun Hospital and Medical School   (South Korea)

^c Kongju National University   (South Korea)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 83455209199     PISSN: 17387949     EISSN: 20929129     Source Type: Journal    
DOI: 10.5045/kjh.2011.46.1.3     Document Type: Note

References (5)

1. Stern-Ginossar N, Mandelboim O. Receptors on NK cells. In: Lotze MT, Thomson AW, eds. Natural killer cells: basic science and clinical application. 1st ed. London, UK: Academic Press, 2010:155-68.
2. Terme M, Ullrich E, Delahaye NF, Chaput N, Zitvogel L. Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol 2008;9:486-94.
3. Cooley S, Miller JS. Clinical trials of NK cells for cancer. In: Lotze MT, Thomson AW, eds. Natural killer cells: basic science and clinical application. 1st ed. London, UK: Academic Press, 2010:555-70.
4. Cho D, Shook DR, Shimasaki N, Chang YH, Fujisaki H, Campana D. Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res 2010;16:3901-9.
5. Bekaii-Saab TS, Roda JM, Guenterberg KD, et al. A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. Mol Cancer Ther 2009;8:2983-91.